P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine P-glycoprotein knockout model

Drug Metabolism and Disposition

Volumn 36, Issue 6, 2008, Pages 1073-1079

  Mealey, Katrina L ^a   Greene, Stephen ^a   Bagley, Rodney ^a   Gay, John ^a   Tucker, Russ ^a   Gavin, Patrick ^a   Schmidt, Kari ^b   Nelson, Frederick ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; GLYCOPROTEIN P; LOPERAMIDE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM DEPRESSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; MALE; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; VALIDATION STUDY; WILD TYPE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DOGS; FEMALE; LOPERAMIDE; MALE; MODELS, ANIMAL; P-GLYCOPROTEIN; TECHNETIUM TC 99M SESTAMIBI;

CANIS FAMILIARIS;

EID: 44149102449     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.018978     Document Type: Article

References (32)

1. Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, and Piscitelli SC (2005) Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 41:1787-1793.
2. Artru AA (1991) Dose-related changes in the rate of CSF formation and resistance to reabsorption of CSF during administration of fentanyl, sufentanil, or alfentanil in dogs. J Neurosurg Anesthesiol 3:283-290.
3. Barrand MA, Robertson KJ, and von Weikersthal SF (1995) Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett 374:179-183.
4. Bendayan R, Lee G, and Bendayan M (2002) Functional expression and localization of Pglycoprotein at the blood brain barrier. Microsc Res Tech 57:365-380.
5. Capparelli EV, Holland D, Okamoto C, Gragg B, Durelle J, Marquie-Beck J, van den BG, Ellis R, and Letendre S (2005) Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19:949-952.
6. Christensen J, Hojskov CS, Dam M, and Poulsen JH (2001) Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit 23:529-535.
7. Dean M (2005) The genetics of ATP-binding cassette transporters. Methods Enzymol 400:409-429.
8. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174.
9. Dyszlewski M, Blake HM, Dahlheimer JL, Pica CM, and Piwnica-Worms D (2002) Characterization of a novel 99mTc-carbonyl complex as a functional probe of MDR1 P-glycoprotein transport activity. Mol Imaging 1:24-35.
10. Feng MR (2002) Assessment of blood-brain barrier penetration: in silico, in vitro and in vivo. Curr Drug Metab 3:647-657.
11. Golden PL and Pollack GM (2003) Blood-brain barrier efflux transport. J Pharm Sci 92:1739-1753.
12. Kwan P and Brodie MJ (2005) Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46:224-235.
13. Lin JH and Yamazaki M (2003) Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35:417-454.
14. Löscher W and Potschka H (2002) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301:7-14.
15. McGee B, Smith N, and Aweeka F (2006) HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 7:142-153.
16. Mealey KL, Bentjen SA, Gay JM, and Cantor GH (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11:727-733.
17. Myles PS, Leslie K, McNeil J, Forbes A, and Chan MT (2004) Bispectral index monitoring to prevent awareness during anaesthesia: the B-Aware randomised controlled trial. Lancet 363:1757-1763.
18. Neff MW, Robertson KR, Wong AK, Safra N, Broman KW, Slatkin M, Mealey KL, and Pedersen NC (2004) Breed distribution and history of canine mdr1-1{Delta}, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci U S A 101:11725-11730.
19. Pardridge WM (1999) Blood-brain barrier biology and methodology. J Neurovirol 5:556-569.
20. Peak S and Abrey LE (2006) Chemotherapy and the treatment of brain metastases. Hematol Oncol Clin North Am 20:1287-1295.
21. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, and Piwnica-Worms D (1999) Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96:3900-3905.
22. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO, and Roux F (1998) Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71:705-715.
23. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
24. Schinkel AH, Wagenaar E, Mol CA, and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524.
25. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, and Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
26. Sills GJ, Kwan P, Butler E, de Lange EC, van den Berg DJ, and Brodie MJ (2002) P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 3:427-432.
27. Skach WR (1998) Topology of P-glycoproteins. Methods Enzymol 292:265-278.
28. Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, and Lotsch J (2003) Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13:651-660.
29. Sugawara I, Hamada H, Tsuruo T, and Mori S (1990) Specialized localization of P-glycoprotein recognized by MRK 16 monoclonal antibody in endothelial cells of the brain and the spinal cord. Jpn J Cancer Res 81:727-730.
30. Thuerauf N and Fromm MF (2006) The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci 256:281-286.
31. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, and Raffel C (1995) MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36:1-6.
32. Yoshimura A, Kuwazuru Y, Sumizawa T, Ichikawa M, Ikeda S, Uda T, and Akiyama S (1989) Cytoplasmic orientation and two-domain structure of the multidrug transporter, P-glycoprotein, demonstrated with sequence-specific antibodies. J Biol Chem 264:16282-16291.